Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Targeted Quantification of Phosphorylation Dynamics in the Context of EGFR-MAPK Pathway.

Yi L, Shi T, Gritsenko MA, X'avia Chan CY, Fillmore TL, Hess BM, Swensen AC, Liu T, Smith RD, Wiley HS, Qian WJ.

Anal Chem. 2018 Apr 17;90(8):5256-5263. doi: 10.1021/acs.analchem.8b00071. Epub 2018 Apr 3.

PMID:
29584399
2.

Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis.

Wang X, Liu B, Searle X, Yeung C, Bogdan A, Greszler S, Singh A, Fan Y, Swensen AM, Vortherms T, Balut C, Jia Y, Desino K, Gao W, Yong H, Tse C, Kym P.

J Med Chem. 2018 Feb 22;61(4):1436-1449. doi: 10.1021/acs.jmedchem.7b01339. Epub 2018 Jan 5.

PMID:
29251932
3.

Compact Ultrahigh-Pressure Nanoflow Capillary Liquid Chromatograph.

Zhao X, Xie X, Sharma S, Tolley LT, Plistil A, Barnett HE, Brisbin MP, Swensen AC, Price JC, Farnsworth PB, Tolley HD, Stearns SD, Lee ML.

Anal Chem. 2017 Jan 3;89(1):807-812. doi: 10.1021/acs.analchem.6b03575. Epub 2016 Dec 20.

PMID:
28105847
4.

Discovery of a potent and selective ROMK inhibitor with improved pharmacokinetic properties based on an octahydropyrazino[2,1-c][1,4]oxazine scaffold.

Zhu Y, de Jesus RK, Tang H, Walsh SP, Jiang J, Gu X, Teumelsan N, Shahripour A, Pio B, Ding FX, Ha S, Priest BT, Swensen AM, Alonso-Galicia M, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Zhou X, Pai LY, Hampton C, Hernandez M, Owens K, Ehrhart J, Roy S, Kaczorowski GJ, Yang L, Parmee ER, Sullivan K, Garcia ML, Pasternak A.

Bioorg Med Chem Lett. 2016 Dec 1;26(23):5695-5702. doi: 10.1016/j.bmcl.2016.10.064. Epub 2016 Oct 24.

PMID:
27839686
5.

Whole blood and urine bioactive Hepcidin-25 determination using liquid chromatography mass spectrometry.

Swensen AC, Finnell JG, Matias C, Gross AJ, Prince JT, Watt RK, Price JC.

Anal Biochem. 2017 Jan 15;517:23-30. doi: 10.1016/j.ab.2016.10.023. Epub 2016 Oct 26.

PMID:
27794422
6.

Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.

DerSarkissian M, Xiao Y, Duh MS, Lefebvre P, Swensen AR, Bell CF.

J Manag Care Spec Pharm. 2016 Oct;22(10):1204-14. doi: 10.18553/jmcp.2016.22.10.1204.

7.

Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart Failure.

Tang H, Zhu Y, Teumelsan N, Walsh SP, Shahripour A, Priest BT, Swensen AM, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Pai LY, Hampton C, Corona A, Hernandez M, Metzger J, Forrest M, Zhou X, Owens K, Tong V, Parmee E, Roy S, Kaczorowski GJ, Yang L, Alonso-Galicia M, Garcia ML, Pasternak A.

ACS Med Chem Lett. 2016 May 12;7(7):697-701. doi: 10.1021/acsmedchemlett.6b00122. eCollection 2016 Jul 14.

8.

Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation.

Walsh SP, Shahripour A, Tang H, de Jesus RK, Teumelsan N, Zhu Y, Frie J, Priest BT, Swensen AM, Alonso-Galicia M, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Zhou X, Pai LY, Hampton C, Hernandez M, Owens K, Ehrhart J, Roy S, Kaczorowski GJ, Yang L, Garcia ML, Pasternak A.

Bioorg Med Chem Lett. 2016 May 1;26(9):2339-43. doi: 10.1016/j.bmcl.2016.03.035. Epub 2016 Mar 12.

PMID:
27017115
9.

Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation.

Walsh SP, Shahripour A, Tang H, Teumelsan N, Frie J, Zhu Y, Priest BT, Swensen AM, Liu J, Margulis M, Visconti R, Weinglass A, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Alonso-Galicia M, Zhou X, Pai LY, Corona A, Hampton C, Hernandez M, Bentley R, Chen J, Shah K, Metzger J, Forrest M, Owens K, Tong V, Ha S, Roy S, Kaczorowski GJ, Yang L, Parmee E, Garcia ML, Sullivan K, Pasternak A.

ACS Med Chem Lett. 2015 May 7;6(7):747-52. doi: 10.1021/ml500440u. eCollection 2015 Jul 9.

10.

Cardiomyocyte mitochondrial respiration is reduced by receptor for advanced glycation end-product signaling in a ceramide-dependent manner.

Nelson MB, Swensen AC, Winden DR, Bodine JS, Bikman BT, Reynolds PR.

Am J Physiol Heart Circ Physiol. 2015 Jul 1;309(1):H63-9. doi: 10.1152/ajpheart.00043.2015. Epub 2015 May 8.

11.

Characterization of the triazine, T4, a representative from a novel series of CaV2 inhibitors with strong state-dependence, poor use-dependence, and distinctively fast kinetics.

Swensen AM, Niforatos W, Lee CH, Jarvis MF, McGaraughty S.

Eur J Pharmacol. 2014 Dec 15;745:234-42. doi: 10.1016/j.ejphar.2014.10.037. Epub 2014 Oct 30.

PMID:
25446431
12.

Cigarette smoke increases cardiomyocyte ceramide accumulation and inhibits mitochondrial respiration.

Tippetts TS, Winden DR, Swensen AC, Nelson MB, Thatcher MO, Saito RR, Condie TB, Simmons KJ, Judd AM, Reynolds PR, Bikman BT.

BMC Cardiovasc Disord. 2014 Nov 22;14:165. doi: 10.1186/1471-2261-14-165.

13.

Ceramides mediate cigarette smoke-induced metabolic disruption in mice.

Thatcher MO, Tippetts TS, Nelson MB, Swensen AC, Winden DR, Hansen ME, Anderson MC, Johnson IE, Porter JP, Reynolds PR, Bikman BT.

Am J Physiol Endocrinol Metab. 2014 Nov 15;307(10):E919-27. doi: 10.1152/ajpendo.00258.2014. Epub 2014 Sep 30.

14.

Insulin increases ceramide synthesis in skeletal muscle.

Hansen ME, Tippetts TS, Anderson MC, Holub ZE, Moulton ER, Swensen AC, Prince JT, Bikman BT.

J Diabetes Res. 2014;2014:765784. doi: 10.1155/2014/765784. Epub 2014 May 18.

15.

Improved Cav2.2 Channel Inhibitors through a gem-Dimethylsulfone Bioisostere Replacement of a Labile Sulfonamide.

Shao PP, Ye F, Chakravarty PK, Herrington JB, Dai G, Bugianesi RM, Haedo RJ, Swensen AM, Warren VA, Smith MM, Garcia ML, McManus OB, Lyons KA, Li X, Green M, Jochnowitz N, McGowan E, Mistry S, Sun SY, Abbadie C, Kaczorowski GJ, Duffy JL.

ACS Med Chem Lett. 2013 Sep 8;4(11):1064-8. doi: 10.1021/ml4002612. eCollection 2013 Nov 14.

16.

Suicide prevention training program for gatekeepers working in community hospice settings.

Matthieu MM, Swensen AB.

J Soc Work End Life Palliat Care. 2014;10(1):95-105. doi: 10.1080/15524256.2013.877865.

PMID:
24628144
17.

Research & services partnerships: lessons learned through a national partnership between clinical leaders and researchers.

Kirchner JE, Kearney LK, Ritchie MJ, Dollar KM, Swensen AB, Schohn M.

Psychiatr Serv. 2014 May 1;65(5):577-9.

PMID:
24585229
18.

Mechanistic insights into the analgesic efficacy of A-1264087, a novel neuronal Ca(2+) channel blocker that reduces nociception in rat preclinical pain models.

Zhu CZ, Vortherms TA, Zhang M, Xu J, Swensen AM, Niforatos W, Neelands T, Milicic I, Lewis LG, Zhong C, Gauvin D, Mikusa J, Zhan C, Pai M, Roderwald V, Chu KL, Cole EE, Bespalov A, Searle XB, McGaraughty S, Bitner RS, Jarvis MF, Bannon AW, Joshi SK, Scott VE, Lee CH.

J Pain. 2014 Apr;15(4):387.e1-14. doi: 10.1016/j.jpain.2013.12.002. Epub 2013 Dec 25.

PMID:
24374196
19.

A mixed Ca2+ channel blocker, A-1264087, utilizes peripheral and spinal mechanisms to inhibit spinal nociceptive transmission in a rat model of neuropathic pain.

Xu J, Chu KL, Zhu CZ, Niforatos W, Swensen A, Searle X, Lee L, Jarvis MF, McGaraughty S.

J Neurophysiol. 2014 Jan;111(2):394-404. doi: 10.1152/jn.00463.2013. Epub 2013 Oct 23.

20.

Pharmacologic inhibition of the renal outer medullary potassium channel causes diuresis and natriuresis in the absence of kaliuresis.

Garcia ML, Priest BT, Alonso-Galicia M, Zhou X, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Liu J, Swensen A, Pai LY, Xiao J, Hernandez M, Hoagland K, Owens K, Tang H, de Jesus RK, Roy S, Kaczorowski GJ, Pasternak A.

J Pharmacol Exp Ther. 2014 Jan;348(1):153-64. doi: 10.1124/jpet.113.208603. Epub 2013 Oct 18.

21.

Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one.

Tang H, de Jesus RK, Walsh SP, Zhu Y, Yan Y, Priest BT, Swensen AM, Alonso-Galicia M, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Zhou X, Pai LY, Hampton C, Hernandez M, Owens K, Roy S, Kaczorowski GJ, Yang L, Garcia ML, Pasternak A.

Bioorg Med Chem Lett. 2013 Nov 1;23(21):5829-32. doi: 10.1016/j.bmcl.2013.08.104. Epub 2013 Sep 6.

PMID:
24075732
22.

Mitochondrial fission mediates ceramide-induced metabolic disruption in skeletal muscle.

Smith ME, Tippetts TS, Brassfield ES, Tucker BJ, Ockey A, Swensen AC, Anthonymuthu TS, Washburn TD, Kane DA, Prince JT, Bikman BT.

Biochem J. 2013 Dec 15;456(3):427-39. doi: 10.1042/BJ20130807.

PMID:
24073738
23.

Synthesis and SAR of 4-aminocyclopentapyrrolidines as orally active N-type calcium channel inhibitors for inflammatory and neuropathic pain.

Beebe X, Yeung CM, Darczak D, Shekhar S, Vortherms TA, Miller L, Milicic I, Swensen AM, Zhu CZ, Banfor P, Wetter JM, Marsh KC, Jarvis MF, Scott VE, Schrimpf MR, Lee CH.

Bioorg Med Chem Lett. 2013 Sep 1;23(17):4857-61. doi: 10.1016/j.bmcl.2013.06.074. Epub 2013 Jul 4.

PMID:
23876987
24.

The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument.

Lebwohl M, Swensen AR, Nyirady J, Kim E, Gwaltney CJ, Strober BE.

Int J Dermatol. 2014 Jun;53(6):714-22. doi: 10.1111/j.1365-4632.2012.05798.x. Epub 2013 Apr 4.

PMID:
23557000
25.

Establishment of a secondary screening assay for P/Q-type calcium channel blockers.

Hermann D, Mezler M, Swensen AM, Bruehl C, Obergrußerger A, Wicke K, Schoemaker H, Gross G, Draguhn A, Nimmrich V.

Comb Chem High Throughput Screen. 2013 Mar;16(3):233-43.

PMID:
23228050
26.

Aminopiperidine sulfonamide Cav2.2 channel inhibitors for the treatment of chronic pain.

Shao PP, Ye F, Chakravarty PK, Varughese DJ, Herrington JB, Dai G, Bugianesi RM, Haedo RJ, Swensen AM, Warren VA, Smith MM, Garcia ML, McManus OB, Lyons KA, Li X, Green M, Jochnowitz N, McGowan E, Mistry S, Sun SY, Abbadie C, Kaczorowski GJ, Duffy JL.

J Med Chem. 2012 Nov 26;55(22):9847-55. doi: 10.1021/jm301056k. Epub 2012 Nov 12.

PMID:
23098566
27.

Synthesis and SAR of 4-aminocyclopentapyrrolidines as N-type Ca²⁺ channel blockers with analgesic activity.

Beebe X, Darczak D, Henry RF, Vortherms T, Janis R, Namovic M, Donnelly-Roberts D, Kage KL, Surowy C, Milicic I, Niforatos W, Swensen A, Marsh KC, Wetter JM, Franklin P, Baker S, Zhong C, Simler G, Gomez E, Boyce-Rustay JM, Zhu CZ, Stewart AO, Jarvis MF, Scott VE.

Bioorg Med Chem. 2012 Jul 1;20(13):4128-39. doi: 10.1016/j.bmc.2012.04.057. Epub 2012 May 4.

PMID:
22626552
28.

An automated electrophysiological assay for differentiating Ca(v)2.2 inhibitors based on state dependence and kinetics.

Swensen AM, Niforatos W, Vortherms TA, Perner RJ, Li T, Schrimpf MR, Scott VE, Lee L, Jarvis MF, McGaraughty S.

Assay Drug Dev Technol. 2012 Dec;10(6):542-50. doi: 10.1089/adt.2011.437. Epub 2012 Mar 19.

PMID:
22428804
29.

Development and validation of a fluorescence-based HTS assay for the identification of P/Q-type calcium channel blockers.

Mezler M, Hermann D, Swensen AM, Draguhn A, Terstappen GC, Gross G, Schoemaker H, Freiberg G, Pratt S, Gopalakrishnan SM, Nimmrich V.

Comb Chem High Throughput Screen. 2012 Jun 1;15(5):372-85.

PMID:
22272661
30.

Characterization of the substituted N-triazole oxindole TROX-1, a small-molecule, state-dependent inhibitor of Ca(V)2 calcium channels.

Swensen AM, Herrington J, Bugianesi RM, Dai G, Haedo RJ, Ratliff KS, Smith MM, Warren VA, Arneric SP, Eduljee C, Parker D, Snutch TP, Hoyt SB, London C, Duffy JL, Kaczorowski GJ, McManus OB.

Mol Pharmacol. 2012 Mar;81(3):488-97. doi: 10.1124/mol.111.075226. Epub 2011 Dec 21.

31.

A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception without altering hemodynamic function in rats.

Scott VE, Vortherms TA, Niforatos W, Swensen AM, Neelands T, Milicic I, Banfor PN, King A, Zhong C, Simler G, Zhan C, Bratcher N, Boyce-Rustay JM, Zhu CZ, Bhatia P, Doherty G, Mack H, Stewart AO, Jarvis MF.

Biochem Pharmacol. 2012 Feb 1;83(3):406-18. doi: 10.1016/j.bcp.2011.10.019. Epub 2011 Nov 16.

PMID:
22153861
32.

Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases.

Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Swensen A, Lefebvre P.

J Asthma. 2011 Nov;48(9):923-30. doi: 10.3109/02770903.2011.618568. Epub 2011 Oct 7. Erratum in: J Asthma. 2012 Apr;49(3):327.

PMID:
21978232
33.

Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001-2007.

Briesacher BA, Quittner AL, Fouayzi H, Zhang J, Swensen A.

Pediatr Pulmonol. 2011 Aug;46(8):770-6. doi: 10.1002/ppul.21441. Epub 2011 Apr 4.

PMID:
21465674
34.

Comparative analysis of inactivated-state block of N-type (Ca(v)2.2) calcium channels.

Vortherms TA, Swensen AM, Niforatos W, Limberis JT, Neelands TR, Janis RS, Thimmapaya R, Donnelly-Roberts DL, Namovic MT, Zhang D, Brent Putman C, Martin RL, Surowy CS, Jarvis MF, Scott VE.

Inflamm Res. 2011 Jul;60(7):683-93. doi: 10.1007/s00011-011-0322-9. Epub 2011 Mar 11.

PMID:
21394563
35.

A potent and selective indole N-type calcium channel (Ca(v)2.2) blocker for the treatment of pain.

Tyagarajan S, Chakravarty PK, Park M, Zhou B, Herrington JB, Ratliff K, Bugianesi RM, Williams B, Haedo RJ, Swensen AM, Warren VA, Smith M, Garcia M, Kaczorowski GJ, McManus OB, Lyons KA, Li X, Madeira M, Karanam B, Green M, Forrest MJ, Abbadie C, McGowan E, Mistry S, Jochnowitz N, Duffy JL.

Bioorg Med Chem Lett. 2011 Jan 15;21(2):869-73. doi: 10.1016/j.bmcl.2010.11.067. Epub 2010 Nov 21.

PMID:
21195616
36.

A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel.

Schmalhofer WA, Swensen AM, Thomas BS, Felix JP, Haedo RJ, Solly K, Kiss L, Kaczorowski GJ, Garcia ML.

Assay Drug Dev Technol. 2010 Dec;8(6):714-26. doi: 10.1089/adt.2010.0351.

PMID:
21158686
37.

Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs.

Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh MS.

Respir Med. 2011 Mar;105(3):435-41. doi: 10.1016/j.rmed.2010.09.006. Epub 2010 Sep 29.

38.

The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review.

Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS.

COPD. 2010 Jun;7(3):214-28. doi: 10.3109/15412555.2010.481697. Review.

PMID:
20486821
39.

Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker.

Abbadie C, McManus OB, Sun SY, Bugianesi RM, Dai G, Haedo RJ, Herrington JB, Kaczorowski GJ, Smith MM, Swensen AM, Warren VA, Williams B, Arneric SP, Eduljee C, Snutch TP, Tringham EW, Jochnowitz N, Liang A, Euan MacIntyre D, McGowan E, Mistry S, White VV, Hoyt SB, London C, Lyons KA, Bunting PB, Volksdorf S, Duffy JL.

J Pharmacol Exp Ther. 2010 Aug;334(2):545-55. doi: 10.1124/jpet.110.166363. Epub 2010 May 3.

40.

The impact of psoriasis on health care costs and patient work loss.

Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G.

J Am Acad Dermatol. 2008 Nov;59(5):772-80. doi: 10.1016/j.jaad.2008.06.043.

PMID:
19119095
41.

Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD.

Mannino DM, Thorn D, Swensen A, Holguin F.

Eur Respir J. 2008 Oct;32(4):962-9. doi: 10.1183/09031936.00012408. Epub 2008 Jun 25.

42.

A high-capacity membrane potential FRET-based assay for the sodium-coupled glucose co-transporter SGLT1.

Weinglass AB, Swensen AM, Liu J, Schmalhofer W, Thomas A, Williams B, Ross L, Hashizume K, Kohler M, Kaczorowski GJ, Garcia ML.

Assay Drug Dev Technol. 2008 Apr;6(2):255-62. doi: 10.1089/adt.2008.125.

PMID:
18471079
43.

A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors.

Dai G, Haedo RJ, Warren VA, Ratliff KS, Bugianesi RM, Rush A, Williams ME, Herrington J, Smith MM, McManus OB, Swensen AM.

Assay Drug Dev Technol. 2008 Apr;6(2):195-212. doi: 10.1089/adt.2008.136.

PMID:
18471074
44.

The direct and indirect cost burden of atopic dermatitis: an employer-payer perspective.

Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G.

Manag Care Interface. 2007 Oct;20(10):26-32.

PMID:
18405204
45.

Novel CaV2.1 clone replicates many properties of Purkinje cell CaV2.1 current.

Richards KS, Swensen AM, Lipscombe D, Bommert K.

Eur J Neurosci. 2007 Nov;26(10):2950-61.

PMID:
18001290
46.

Automated electrophysiology in drug discovery.

Priest BT, Swensen AM, McManus OB.

Curr Pharm Des. 2007;13(23):2325-37. Review.

PMID:
17692004
47.
48.

Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients.

Swensen A, Birnbaum HG, Ben Hamadi R, Greenberg P, Cremieux PY, Secnik K.

J Adolesc Health. 2004 Oct;35(4):346.e1-9.

PMID:
15830457
49.
50.

Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000.

Birnbaum HG, Kessler RC, Lowe SW, Secnik K, Greenberg PE, Leong SA, Swensen AR.

Curr Med Res Opin. 2005 Feb;21(2):195-206.

PMID:
15801990

Supplemental Content

Loading ...
Support Center